BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 8380125)

  • 1. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: participation of plasminogen activator and its inhibitor in matrix degradation.
    Shirasuna K; Saka M; Hayashido Y; Yoshioka H; Sugiura T; Matsuya T
    Cancer Res; 1993 Jan; 53(1):147-52. PubMed ID: 8380125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
    Niedbala MJ; Sartorelli AC
    Cancer Commun; 1990; 2(5):189-99. PubMed ID: 2142433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix.
    Niedbala MJ; Sartorelli AC
    Cancer Res; 1989 Jun; 49(12):3302-9. PubMed ID: 2497975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular matrix produced by cultured corneal and aortic endothelial cells contains active tissue-type and urokinase-type plasminogen activators.
    Korner G; Bjornsson TD; Vlodavsky I
    J Cell Physiol; 1993 Mar; 154(3):456-65. PubMed ID: 8436596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of human squamous cell carcinoma plasma membrane associated urokinase plasminogen activator by epidermal growth factor.
    Niedbala MJ; Bajetta S; Carbone R; Sartorelli AC
    Cancer Commun; 1990; 2(9):317-24. PubMed ID: 2169831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Involvement of both heparanase and plasminogen activator in lymphoma cell-mediated degradation of heparan sulfate in the subendothelial extracellular matrix.
    Bar-Ner M; Mayer M; Schirrmacher V; Vlodavsky I
    J Cell Physiol; 1986 Aug; 128(2):299-306. PubMed ID: 2426287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of urokinase plasminogen activator (uPA) activity by E-cadherin and hormones in mammary epithelial cells.
    Sasaki CY; Lin H; Passaniti A
    J Cell Physiol; 1999 Oct; 181(1):1-13. PubMed ID: 10457348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the plasminogen activator and matrix metalloproteinase systems in epidermal growth factor- and scatter factor-stimulated invasion of carcinoma cells.
    Rosenthal EL; Johnson TM; Allen ED; Apel IJ; Punturieri A; Weiss SJ
    Cancer Res; 1998 Nov; 58(22):5221-30. PubMed ID: 9823336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimulation of human breast carcinoma cell invasiveness and urokinase plasminogen activator activity by glucose deprivation.
    Belkacemi L; Lam E; Caldwell JD; Siemens DR; Graham CH
    Exp Cell Res; 2006 Jun; 312(10):1685-92. PubMed ID: 16564525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the urokinase receptor regulates focal adhesion assembly and cell migration in adenoid cystic carcinoma cells.
    Abu-Ali S; Sugiura T; Takahashi M; Shiratsuchi T; Ikari T; Seki K; Hiraki A; Matsuki R; Shirasuna K
    J Cell Physiol; 2005 May; 203(2):410-9. PubMed ID: 15521066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cancer cell urokinase plasminogen activator by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.
    Baker MS; Bleakley P; Woodrow GC; Doe WF
    Cancer Res; 1990 Aug; 50(15):4676-84. PubMed ID: 2114945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines.
    Shiratsuchi T; Ishibashi H; Shirasuna K
    J Cell Physiol; 2002 Dec; 193(3):340-8. PubMed ID: 12384986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The plasminogen-activating system in hepatic stellate cells.
    Leyland H; Gentry J; Arthur MJ; Benyon RC
    Hepatology; 1996 Nov; 24(5):1172-8. PubMed ID: 8903394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of a truncated form of the urokinase-type plasminogen-activator receptor in normal and tumor thyroid cells.
    Ragno P; Montuori N; Covelli B; Hoyer-Hansen G; Rossi G
    Cancer Res; 1998 Mar; 58(6):1315-9. PubMed ID: 9515821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibronectin degradation by human gastric carcinoma cell lines and its associated proteases in relation to stromal invasion in nude mice.
    Wakabayashi H; Kawaguchi T
    Invasion Metastasis; 1992; 12(5-6):284-300. PubMed ID: 1298740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis.
    Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG
    Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of fibrinolytic activity of bovine aortic endothelial cells by ginsenoside Rb2.
    Liu JW; Wei DZ; Du CB; Zhong JJ
    Acta Pharmacol Sin; 2003 Feb; 24(2):102-8. PubMed ID: 12546716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the plasminogen system in bone resorption in vitro.
    Daci E; Udagawa N; Martin TJ; Bouillon R; Carmeliet G
    J Bone Miner Res; 1999 Jun; 14(6):946-52. PubMed ID: 10352103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants.
    Mazzieri R; Masiero L; Zanetta L; Monea S; Onisto M; Garbisa S; Mignatti P
    EMBO J; 1997 May; 16(9):2319-32. PubMed ID: 9171346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. uPA and uPAR contribute to NK cell invasion through the extracellular matrix.
    Al-Atrash G; Kitson RP; Xue Y; Mazar AP; Kim MH; Goldfarb RH
    Anticancer Res; 2001; 21(3B):1697-704. PubMed ID: 11497249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.